Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Bisnorcymserine (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; First in man
- 13 Jul 2018 Planned End Date changed from 3 Jul 2018 to 3 Jul 2019.
- 13 Jul 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 06 Jul 2017 Planned End Date changed from 3 Jul 2017 to 3 Jul 2018.